As an impaired Keap1-Nrf2 system is induced by mutation or hypermethylation in several types of human cancer, we hypothesized that mutation or epigenetic changes of KEAP1 may decrease Keap1 expression and increase Nrf2 activity and transactivation of its downstream genes in CRC. This evidence concerns the gene KEAP1 and cancer.